Pharma channel feed

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

7 years ago

FDA ap­proves trail­blaz­ing post­par­tum de­pres­sion ther­a­py, in cru­cial mile­stone for wom­en's health

7 years ago

Skin re­gen­er­a­tion com­pa­ny Po­lar­i­tyTE re­veals SEC in­ves­ti­ga­tion, prob­ing in­to its lead prod­uct, for­mer CFO and cur­rent in­vestors

7 years ago

Roche stacks up Tecen­triq nods, fol­low­ing up breast can­cer ap­proval with small cell lung can­cer

7 years ago

Bio­haven is bet­ting hun­dreds of mil­lions it can hus­tle ahead of ri­vals in a block­buster race. A quick M&A deal could pay off back­ers big time

7 years ago

Scott Got­tlieb to bio­phar­ma: You want­ed us to help mod­ern­ize R&D, now go out and do it

7 years ago

Roche clinch­es EU ap­proval for MabThera in rare au­toim­mune in­di­ca­tion — will it boost dwin­dling sales amid biosimi­ar com­pe­ti­tion?

7 years ago

Mer­ck notch­es fourth lung can­cer ap­proval in Eu­rope for flag­ship Keytru­da

7 years ago

End­points News poll: In­dus­try in­sid­ers of­fer a big 👍 for Ned Sharp­less

7 years ago
People

US law­mak­ers now want to hear from the mid­dle­men PBMs to un­pack their role in drug pric­ing

7 years ago

Less than a year af­ter Rho­pres­sa launch, Aerie scores new glau­co­ma drug ap­proval

7 years ago

FDA un­veils 5 guid­ances on broad­en­ing can­cer clin­i­cal tri­al el­i­gi­bil­i­ty

7 years ago

NCI's Ned Sharp­less gets the nod to run the FDA in wake of Scott Got­tlieb’s sur­prise ex­it

7 years ago
People

Trump's White House pro­pos­es raft of cuts to sci­ence R&D bud­gets, but FDA scores high­er funds

7 years ago

FDA of­fers quick thumbs up to ex­pand Dupix­en­t's atopic der­mati­tis la­bel as Re­gen­eron/Sanofi plot block­buster moves

7 years ago

EMA launch­es op­er­a­tions in Am­s­ter­dam

7 years ago

As­traZeneca lines up a $20M in­stall­ment plan to launch a new on­col­o­gy col­lab­o­ra­tion with mi­cro­bio­me play­er Seres

7 years ago

Is sec­ond time the charm for ozan­i­mod? Cel­gene starts to find out with EMA fil­ing

7 years ago

Prin­cip­ia, Ab­b­Vie walk away from 2017 part­ner­ship for in­flam­ma­to­ry, au­toim­mune drugs

7 years ago

Roche claims a first in breast can­cer as Tecen­triq/Abrax­ane com­bo nabs quick ap­proval in front­line use

7 years ago

FDA ex­perts gun down a big part of Sanofi's pitch for their con­tro­ver­sial vac­cine

7 years ago

FDA re­vers­es course, de­cides not to add suf­fix­es to old­er bi­o­log­ics’ non­pro­pri­etary names

7 years ago

'We can't': Jeff Lei­den stands his ground as MPs grill Ver­tex on pric­ing dis­agree­ment with NHS

7 years ago

Pri­vate on­col­o­gy out­fit Onc­ter­nal us­es GTx as shell to make Nas­daq de­but

7 years ago
First page Previous page 277278279280281282283 Next page Last page
A service from the Financial Times